Compare SOBR & HCWB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SOBR | HCWB |
|---|---|---|
| Founded | 2004 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Newspapers/Magazines | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3M | 3.7M |
| IPO Year | 2008 | 2021 |
| Metric | SOBR | HCWB |
|---|---|---|
| Price | $0.96 | $0.91 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $35.00 |
| AVG Volume (30 Days) | 158.5K | ★ 19.4M |
| Earning Date | 04-14-2026 | 03-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 72.19 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $212,736.00 | ★ $4,099,750.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 35.25 | N/A |
| 52 Week Low | $0.46 | $0.22 |
| 52 Week High | $7.70 | $17.80 |
| Indicator | SOBR | HCWB |
|---|---|---|
| Relative Strength Index (RSI) | 51.98 | 58.36 |
| Support Level | $0.67 | $0.49 |
| Resistance Level | $2.19 | $1.35 |
| Average True Range (ATR) | 0.10 | 0.14 |
| MACD | 0.05 | 0.06 |
| Stochastic Oscillator | 70.75 | 58.77 |
Sobr Safe Inc provides non-invasive technology to quickly and humanely identify the presence of alcohol in individuals. Its technologies are integrated within robust and scalable data platform, producing statistical and measurable user and business data. It developed the scalable, patent-pending ea4 software platform for non-invasive alcohol detection and identity verification, a solution that has current and potential applications. It generates revenue through various combinations of software products and services which include the sale of cloud-based software solutions, detection and data collection hardware devices, and cloud-based data reporting and analysis services.
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.